Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.07.020
Annals of Surgical Oncology 12:354-363 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koga, Y.
Right arrow Articles by Miyazaki, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koga, Y.
Right arrow Articles by Miyazaki, K.

Original Article

Tumor Progression Through Epigenetic Gene Silencing of O6–Methylguanine-DNA Methyltransferase in Human Biliary Tract Cancers

Yasuo Koga, MD1, Yoshihiko Kitajima, MD, PhD1, Atsushi Miyoshi, MD1, Ken Sato, MD1, Kenji Kitahara, MD, PhD1, Hidenobu Soejima, MD, PhD2 and Kohji Miyazaki, MD, PhD1

1 Department of Surgery, Saga University Faculty of Medicine, Nabeshima 5-1-1, Saga, 849-8501, Japan
2 Department of Biomolecular Sciences, Division of Molecular Biology & Genetics, Saga University Faculty of Medicine, Nabeshima 5-1-1, Saga, 849-8501, Japan

Correspondence: Address correspondence and reprint requests to: Kohji Miyazaki, MD, PhD; E-mail: miyazak2{at}post.saga-med.ac.jp

Background: We previously demonstrated in an immunohistochemical study that reduced expression of O6–methylguanine-DNA methyltransferase (MGMT) correlated with a poorer prognosis in patients with biliary tract cancers. The purpose of this study was to clarify how MGMT deficiency leads to a poor outcome in biliary tract cancer. Thus, we examined epigenetic (promoter methylation) and genetic (gene mutation) alterations in biliary tract cancer.

Methods: We examined 37 biliary tract cancer specimens from patients who underwent surgical resection. Promoter methylation was determined by one-step or two-step methylation-specific polymerase chain reaction. Gene mutation was identified by direct sequencing. The expression of MGMT protein in paraffin-embedded tissue was examined by immunohistochemistry.

Results: Frequencies of promoter methylation were 70% for p16/INK4a, 49% for MGMT, 46% for hMLH1, 41% for E-cadherin, and 32% for DAPK genes. MGMT methylation status was closely correlated with the MGMT protein expression determined by immunohistochemistry (P < .001). Although this was not statistically significant, biliary tract cancer tumors with MGMT methylation expressed multigene methylation more frequently than tumors without MGMT methylation (P = .071). A total of 33 mutations were identified in 4 cancer-related genes: p53, K-ras, ß-catenin, and p16/INK4a genes. The most common mutation was GC to AT transitions (58%), which were significantly associated with MGMT promoter methylation (P = .011). These findings suggest that loss of MGMT expression by promoter methylation results in accumulation of GC to AT gene mutations.

Conclusions: Reduced MGMT expression may increase the malignant potential of biliary tract cancer through both epigenetic and genetic mechanisms.

Key Words: DNA alkylation • DNA repair gene • MGMT • Biliary tract cancer • Multigene methylation • Gene mutation






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.